| P50 | author | John Anthony Hardy | Q6237755 |
| | Gareth Williams | Q56948825 |
| | Clive Ballard | Q40279915 |
| P2093 | author name string | William Mobley | |
| | Anne Corbett | |
| P2860 | cites work | The sequence of human chromosome 21 and implications for research into Down syndrome | Q21194900 |
| | Down Syndrome and Attention-Deficit/Hyperactivity Disorder (ADHD) | Q22241820 |
| | Prospects for Improving Brain Function in Individuals with Down Syndrome | Q22252566 |
| | Polymorphic tetranucleotide repeat site within intron 7 of the beta-amyloid precursor protein gene and its lack of association with Alzheimer's disease | Q46187894 |
| | Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology | Q46367075 |
| | Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome | Q46456132 |
| | Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships | Q46464782 |
| | Cognitive impairment in adults with Down's syndrome: similarities to early cognitive changes in Alzheimer's disease | Q46759961 |
| | Influence of the amyloid precursor protein locus on dementia in Down syndrome | Q47376592 |
| | Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. | Q47883705 |
| | Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome | Q47945389 |
| | Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease | Q48266946 |
| | Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome | Q48339041 |
| | Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study | Q48386841 |
| | Phenotype associated with APP duplication in five families | Q48426137 |
| | Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease | Q48484137 |
| | Down's syndrome: Is there a decreased population of neurons? | Q48653422 |
| | DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects | Q48664609 |
| | Some morphometric observations on the brains of patients with Down's syndrome: their relationship to age and dementia | Q48870057 |
| | The natural history of dementia in Down's syndrome | Q49086973 |
| | Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. | Q49122782 |
| | Demographic characteristics, health conditions, and residential service use in adults with Down syndrome in 25 U.S. states. | Q50430642 |
| | Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. | Q50973704 |
| | α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. | Q51875589 |
| | Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. | Q51923343 |
| | Dementia in people with Down's syndrome. | Q51961412 |
| | Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. | Q51964234 |
| | Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. | Q51975752 |
| | Effects of increasing task load on memory impairment in adults with Down syndrome. | Q51989837 |
| | Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. | Q52036701 |
| | A prospective study of Alzheimer disease in Down syndrome. | Q52114487 |
| | APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. | Q52166517 |
| | A four year prospective study of age-related cognitive change in adults with Down's syndrome. | Q52181459 |
| | Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. | Q53201936 |
| | The microtubule associated protein Tau gene and Alzheimer's disease--an association study and meta-analysis. | Q53244969 |
| | Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. | Q53286743 |
| | Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome. | Q53322507 |
| | Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. | Q53363278 |
| | Alzheimer's disease | Q55880664 |
| | A Pilot Study Examining Associations between DYRK1A and a-Synuclein Dementias | Q61902986 |
| | The Extended Tau Haplotype and the Age of Onset of Dementia in Down Syndrome | Q61903250 |
| | Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation | Q84523946 |
| | Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome | Q85195205 |
| | Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study | Q85849603 |
| | Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome | Q87698297 |
| | Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau | Q24648590 |
| | The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease | Q24656574 |
| | A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome | Q26798983 |
| | Molecular mechanisms of cellular cholesterol efflux | Q27021139 |
| | Human neural progenitor cell engraftment increases neurogenesis and microglial recruitment in the brain of rats with stroke | Q27334229 |
| | Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate | Q28205049 |
| | Interplay of Cu,Zn superoxide dismutase and nitric oxide synthase in neurodegenerative processes | Q28237654 |
| | APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy | Q28259007 |
| | Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy | Q28282855 |
| | Interactive effects of physical activity and APOE-ε4 on BOLD semantic memory activation in healthy elders | Q28384123 |
| | The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 |
| | Neuroimaging of individuals with Down’s syndrome at-risk for dementia: Evidence for possible compensatory events | Q30051683 |
| | Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer | Q30459302 |
| | The use of mouse models to understand and improve cognitive deficits in Down syndrome | Q30474023 |
| | Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial | Q30584897 |
| | Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. | Q31146509 |
| | Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. | Q32059477 |
| | Regional and cellular gene expression changes in human Huntington's disease brain | Q33233457 |
| | Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. | Q33412381 |
| | Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model | Q33598454 |
| | Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue | Q33628651 |
| | A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells. | Q33637811 |
| | Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. | Q33667620 |
| | Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome | Q33830061 |
| | Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). | Q33935314 |
| | Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome | Q34010790 |
| | A searchable cross-platform gene expression database reveals connections between drug treatments and disease | Q34123013 |
| | A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease | Q34177042 |
| | Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia | Q34246990 |
| | Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome | Q34344488 |
| | Plasma ß-amyloid and cognitive decline | Q34424794 |
| | Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). | Q34457084 |
| | Positive and negative regulation of APP amyloidogenesis by sumoylation. | Q34467706 |
| | NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. | Q34504363 |
| | Expression of APP pathway mRNAs and proteins in Alzheimer's disease | Q34640815 |
| | The role of DYRK1A in neurodegenerative diseases | Q34642120 |
| | Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. | Q34918986 |
| | Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac). | Q35045125 |
| | Defective mitochondrial function in vivo in skeletal muscle in adults with Down's syndrome: a 31P-MRS study | Q35082737 |
| | Sorting nexin 27 regulates Aβ production through modulating γ-secretase activity | Q35084436 |
| | Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice | Q35177041 |
| | Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome | Q35551607 |
| | Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS). | Q35559764 |
| | Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome | Q35681808 |
| | Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations | Q35745983 |
| | Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia | Q35977798 |
| | Down syndrome, Alzheimer's disease and seizures | Q36111053 |
| | Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome. | Q36253572 |
| | Mitochondrial retrograde signaling regulates neuronal function | Q36268449 |
| | Mouse models of cognitive disorders in trisomy 21: a review | Q36416234 |
| | Norepinephrine Protects against Amyloid-β Toxicity via TrkB. | Q36467129 |
| | Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. | Q36495294 |
| | Dementia and mortality in persons with Down's syndrome | Q36589359 |
| | Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome | Q36983170 |
| | Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. | Q37060457 |
| | Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis | Q37113208 |
| | The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies | Q37259226 |
| | Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome | Q37272579 |
| | Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. | Q37273874 |
| | The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome | Q37455779 |
| | Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome | Q37503442 |
| | Nerve growth factor metabolic dysfunction in Down's syndrome brains. | Q37590669 |
| | Biomarker modeling of Alzheimer's disease | Q37592824 |
| | Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome | Q37671444 |
| | Atypical aging in Down syndrome | Q38129325 |
| | New insights into the therapeutic potential of Girk channels. | Q38165545 |
| | The Role of PICALM in Alzheimer's Disease | Q38245888 |
| | DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications | Q38386156 |
| | Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians | Q39101995 |
| | Associations between cognitively stimulating leisure activities, cognitive function and age-related cognitive decline. | Q39165727 |
| | Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome | Q39249843 |
| | Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation | Q40205410 |
| | BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome | Q40260424 |
| | The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome | Q40489326 |
| | Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia | Q40541309 |
| | Seizures associated with fluoxetine therapy | Q40742738 |
| | Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance | Q42044617 |
| | Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. | Q42467654 |
| | Minocycline prevents cholinergic loss in a mouse model of Down's syndrome | Q42468778 |
| | A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors | Q42912519 |
| | Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2. | Q43258916 |
| | Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. | Q43497931 |
| | The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome | Q43835260 |
| | Lack of association between the polymorphisms of beta-site APP-cleaving enzyme 2 (BACE2) 5'-flanking region and sporadic Alzheimer's disease | Q44073903 |
| | Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis | Q44149270 |
| | Cognitive decline in Down syndrome. | Q44520905 |
| | Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. | Q46020053 |
| | Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease | Q46121331 |
| | Parallel Compensatory and Pathological Events Associated with Tau Pathology in Middle Aged Individuals with Down Syndrome | Q46148617 |
| | Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans | Q46157547 |
| | An experimental approach to detecting dementia in Down syndrome: a paradigm for Alzheimer's disease | Q46187030 |
| P433 | issue | 6 | |
| P921 | main subject | dementia | Q83030 |
| P304 | page(s) | 622-636 | |
| P577 | publication date | 2016-04-11 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Dementia in Down's syndrome | |
| P478 | volume | 15 | |